Key Features of Our Multi-Omics Breakthrough Platform
Assay Time
<4 Hrs Muti-omic analysis
sensitivity
Attomolar (10^-18) sensitivity
Non-Invasive
Urine & Blood
dynamic range
8 logs
Simple
No Amplification or Extraction
Reproducible
CV <3%
Multi-Omics
Simultaneous Detection of DNAs, RNA's, proteins and small molecules.
Comparative Analysis
Traditional Assay
(Single, Multiplex)
Multiple biomarkers, typically one type. Mostly DNA based.
Requires extraction and amplification.
Lacks sensitivity.
Requires complex machinery, data analysis, requiring expertise.
Assay time 12-24 hrs.
Multi-Omics Integration Platform (MIP)
Simultaneous detection of DNAs, RNAs, proteins, and small molecules.
No extraction or amplification.
Ultra attomolar sensitivity.
Simplified, quantifiable, unbiased analysis readout from a basic plate reader.
Assay time <4 hr
Multi-omics Detection, made simple
Play Video
Our Oncology Product Pipeline
Product Name
BCDx Monitoring
BCDx Detect
Advanced Prostate Cancer (co-development with Mayo Clinic)
Sample Type
Urine
Urine
N/D
Clinical Decision
Active surveillance
Early Detection
N/D
R&D
Analytical Validation
Clinical Validation
Launch
Product Name
BCDx Monitoring
Sample Type
Urine
Clinical Decision
Active surveillance
R&D
Analytical Validation
Clinical Validation
Launch
Product Name
BCDx Detect
Sample Type
Urine
Clinical Decision
Early Detection
R&D
Analytical Validation
Clinical Validation
Launch
Product Name
Advanced Prostate Cancer (co-development w/ Mayo Clinic)
Sample Type
N/D
Clinical Decision
N/D
R&D
Analytical Validation
Clinical Validation
Launch
BCDX for Non-invasive Bladder Cancer Monitoring
Patients under active surveillance for bladder cancer monitoring are currently monitored by invasive and costly cystoscopies.
Our 12-marker multi-omics urine test can rule-out bladder cancer in patient for recurrence.
Non-invasive
Urine-based test to monitor for recurrence.
Accurate
100% negative predictive value.
Ultrasensitive
Attomolar (10^-18) sensitivity.
Quick
Can perform in any size urology lab with a simple plate reader. Resuls available in less than an hour.
Proprietary
Patent by international-scope PCT application.
Market Size
>800,000 people in the US living with bladder cancer present annually up to 3 to 4 times a year for evaluation.
If you have bladder cancer questions, Bladder Cancer Advocacy Network (BCAN) is a wonderful, caring website to visit. EIG has no financial or any affiliation with BCAN.